| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 256 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| VASO Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | Vaso announces divestiture of VasoHealthcare for $0.8M | 1 | Seeking Alpha | ||
| 19.11.25 | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 440 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen | |
| 14.11.25 | Vasomedical reports Q3 results | 1 | Seeking Alpha | ||
| 14.11.25 | Vaso Corporation Announces Financial Results for Third Quarter of 2025 | 254 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 02.09.25 | Telescope Innovations Corp.: Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer | 438 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader... ► Artikel lesen | |
| 15.05.25 | Vaso Corporation Announces Financial Results for First Quarter of 2025 | 288 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 31.03.25 | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024 | 266 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services,... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 46,125 | -0,10 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| ASTRAZENECA | 171,55 | +5,12 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 05.02.2026 | Das Instrument ZEG GB0009895292 ASTRAZENECA PLC DI DL-,25 EQUITY hat seinen letzten Handelstag am 05.02.2026: CONTINUOUS TRADING WITH AUCTIONS, PAG UKI0, SettlCurr EUR, CCP Y
The instrument ZEG GB0009895292... ► Artikel lesen | |
| EYEPOINT | 10,710 | -5,93 % | RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline | ||
| IONIS PHARMACEUTICALS | 69,96 | -1,27 % | Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | ||
| WAYLAND GROUP | - | - | EQS-News: Berger Montague (Canada) PC: Ankündigung der Anhörung zur Genehmigung des Vergleichs - Wayland Group Corp., Scott Langille, Gerhard Müller, Paul Pathak, Eric Silver, M. Stein, John Does 1-3, Canaccord Genuity Corp. und RF Securities Clearing LP | EQS-News: Berger Montague (Canada) PC
/ Schlagwort(e): Rechtssache/Sonstiges
ANKÜNDIGUNG DER ANHÖRUNG ZUR GENEHMIGUNG DES VERGLEICHS - KURZFASSUNG - WAYLAND... ► Artikel lesen | |
| CSPC PHARMA | 1,107 | -0,27 % | HSI Closes at 27,183, Up 155 pts; HSTI Closes at 5,451, Up 33 pts; CSPC PHARMA Up over 5%; ZTO EXPRESS-W, WH GROUP, BOC HONG KONG, WHARF REIC, HANG LUNG PPT Hit New Highs; Market Turnover Rises | ||
| SELLAS LIFE SCIENCES | 3,085 | -2,37 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,095 | +0,03 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | - Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,680 | -3,53 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 | ||
| MADRIGAL PHARMACEUTICALS | 403,80 | +0,27 % | Suzhou Ribo Life Science Co., Ltd.: Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,054 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger | CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company"), today announced that it has commenced an exchange offer (the "Offer") involving... ► Artikel lesen | |
| CHUGAI PHARMACEUTICAL | 49,190 | +0,57 % | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| OPUS GENETICS | 2,750 | -6,46 % | Opus Genetics, Inc.: Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa | The trial is funded through Abu Dhabi's Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,380 | -0,45 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen |